X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Novartis expands its portfolio with chinook's renal pipeline having 2 assets, CHK-01 (atrasentan hydrochloride), an oral endothelin A receptor antagonist and BION-1301 (zigakibart), an anti-APRIL monoclonal antibody, for Immunoglobulin A Nephropathy.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Product Name: CHK-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $3,500.0 million Upfront Cash: $3,500.0 million
Deal Type: Acquisition August 11, 2023
Details:
BION-1301 (zigakibart) is a novel anti-APRIL monoclonal antibody with a potentially disease-modifying approach to treating IgA nephropathy by depleting Gd-IgA1, the pathogenic IgA variant, and reducing proteinuria.
Lead Product(s): Zigakibart
Therapeutic Area: Nephrology Product Name: BION-1301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2023
Details:
Through the acquisition, Novartis expands its portfolio with chinook's renal pipeline having 2 assets, CHK-01 (atrasentan hydrochloride), an oral endothelin A receptor antagonist and BION-1301 (zigakibart), an anti-APRIL monoclonal antibody, for Immunoglobulin A Nephropathy.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Product Name: CHK-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $3,500.0 million Upfront Cash: $3,500.0 million
Deal Type: Acquisition June 12, 2023
Details:
The companies will leverage Chinook’s precision medicine approach and expertise in nephrology and Ionis’ expertise in RNA-targeted therapeutics for discovery, development and commercialization of an antisense oligonucleotide therapy for a rare, severe chronic kidney disease.
Lead Product(s): Antisense Oligonucleotide-based Therapy
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Ionis Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 16, 2023
Details:
CHK-336 is an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias. It is being evaluated in a phase 1 clinical trial in healthy volunteers.
Lead Product(s): CHK-336
Therapeutic Area: Genetic Disease Product Name: CHK-336
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2023
Details:
Atrasentan (CHK-01), is a potent and selective endothelin A receptor antagonist that has the potential to provide benefit in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preserve kidney function.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Product Name: CHK-01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
BION-1301 is a humanized IgG4 monoclonal antibody that blocks APRIL, a TNF-family cytokine believed to be implicated in IgAN and other indications, from binding to its receptors.
Lead Product(s): BION-1301
Therapeutic Area: Nephrology Product Name: BION-1301
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2022
Details:
Chinook intends to use the net proceeds from this offering to continue its phase 3 ALIGN and phase 2 AFFINITY trials of atrasentan, fund a phase 3 clinical trial of BION-1301, continue development of CHK-336 and prepare for the potential commercial launch of atrasentan.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Product Name: CHK-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SVB Securities
Deal Size: $105.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 25, 2022
Details:
CHK-01 (atrasentan) is a potent and selective inhibitor of the endothelin A receptor that has potential to provide benefit in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preserve kidney function.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Product Name: CHK-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2022
Details:
BION-1301 is a novel anti-APRIL monoclonal antibody currently in phase 1/2 clinical development for patients with IgAN. Blocking APRIL is a potentially disease-modifying approach to treating IgAN by reducing circulating levels of galactose-deficient IgA1 (Gd-IgA1).
Lead Product(s): BION-1301
Therapeutic Area: Nephrology Product Name: BION-1301
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Evotec
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
